Year Founded
2020
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
mRNA therapeuticsRNA therapeutics

Esperovax General Information

Developing oral mRNA delivery platform with initial focus on COVID-19 vaccine and colorectal cancer therapeutics. Platform includes proprietary circular RNA technology (HercRNA) and two delivery vehicles - virus like particles (VLPs) and graphene nanoparticles (GNPs).

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Plymouth, Michigan
United States

Drug Pipeline

Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Esperovax's pipeline data

Book a demo

Key Partnerships

Ginkgo Bioworks, University of Michigan

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Esperovax Funding

Deal TypeDateAmountStatusStage
Later Stage VCOct 3, 2023$1.0MCompletedPreclinical
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Esperovax's complete valuation and funding history, request access »

Esperovax Investors

Michigan Rise
Investor Type: Venture Capital
Holding: Minority